Antiretroviral combination therapy
The present invention provides combinations comprising a viral maturation inhibitor and another therapeutically effective pharmaceutical agent. The invention is also directed to methods of treating a viral infection by administering such combinations.
1 . A combination comprising a first maturation inhibitor and an antiretroviral agent selected from the group consisting of a protease inhibitor, a reverse transcriptase inhibitor, an integrase inhibitor, a CCR5 antagonist, a fusion inhibitor, and a second maturation inhibitor in amounts effective for treatment of HIV when used in a combination therapy.
2 . The combination of claim 1 wherein the first maturation inhibitor is 3-O-(3′,3′-dimethylsuccinyl)betulinic acid or a pharmaceutically acceptable salt thereof.
3 . The combination of claim 1 wherein the antiretroviral agent is a protease inhibitor.
4 . The combination of claim 3 wherein the protease inhibitor is selected from the group consisting of ritonavir, lopinavir, saquinavir, amprenavir, fosamprenavir, nelfinavir (AG1343), tipranavir, indinavir, atazanavir, brecanavir, TMC-126, darunavir, mozenavir (DMP-450), JE-2147 (AG1776), L-756423 (R-944), KNI-272, DPC-681, DPC-684, SC-52151, BMS 186318, SC-55389a, DMP-323, KNI-227, KIN-272, L697639, PL-100, PPL-100, AG-1859, RO-033-4649, GW-0385, DMP-850, DMP-851, Nar-DG-35, and BMS-232632.
5 . The combination of claim 4 wherein the protease inhibitor is ritonavir.
6 . The combination of claim 4 wherein the protease inhibitor is nelfinavir.
7 . The combination of claim 4 wherein the protease inhibitor is saquinavir.
8 . The combination of claim 4 wherein the protease inhibitor is tipranavir.
9 . The combination of claim 5 wherein the combination further comprises lopinavir.
10 . The combination of claim 4 wherein the protease inhibitor is indinavir.
11 . The combination of claim 4 wherein the protease inhibitor is fosamprenavir.
12 . The combination of claim 4 wherein the protease inhibitor is atazanavir.
13 . The combination of claim 4 wherein the protease inhibitor is brecanavir.
14 . The combination of claim 1 wherein the antiretroviral agent is a reverse transcriptase inhibitor.
15 . The combination of claim 14 wherein the reverse transcriptase inhibitor is selected from the group consisting of nucleoside reverse transcriptase inhibitors, nucleotide reverse transcriptase inhibitors, and non-nucleoside reverse transcriptase inhibitors.
16 . The combination of claim 15 wherein the reverse transcriptase inhibitor is a nucleoside reverse transcriptase inhibitor.
17 . The combination of claim 16 wherein the nucleoside reverse transcriptase inhibitor is selected from the group consisting of lamivudine, zidovudine, emtricitabine, abacavir, lamivudine, zalcitabine, didanosine, stavudine, dideoxycytidine, azidothymidine, alovudine, amdoxovir, dexelvucitabine, dioxolane thymidine, elvucitabine, AVX754, DPC-817, KP-1461, MIV-210, racemic emtricitabine, GSK640385, and GSK-204937.
18 . The combination of claim 16 wherein the nucleoside reverse transcriptase inhibitor is a thiacytidine nucleoside analog reverse transcriptase inhibitor.
19 . The combination of claim 18 wherein the thiacytidine nucleoside analog reverse transcriptase inhibitor is emtricitabine.
20 . The combination of claim 16 wherein the nucleoside reverse transcriptase inhibitor is AVX754.
21 . The combination of claim 15 wherein the reverse transcriptase inhibitor is a nucleotide reverse transcriptase inhibitor.
22 . The combination of claim 21 wherein the nucleotide reverse transcriptase inhibitor is tenofovir disoproxil fumarate.
23 . The combination of claim 15 wherein the reverse transcriptase inhibitor is a non-nucleoside reverse transcriptase inhibitor.
24 . The combination of claim 23 wherein the non-nucleoside reverse transcriptase inhibitor is selected from the group consisting of diaryltriazine reverse transcriptase inhibitors, and diarylpyrimidines reverse transcriptase inhibitors.
25 . The combination of claim 24 wherein the non-nucleoside reverse transcriptase inhibitor is a diarylpyrimidine reverse transcriptase inhibitor.
26 . The combination of claim 25 wherein the diarylpyrimidine non-nucleoside reverse transcriptase inhibitor is selected from the group consisting of etravirine and R278474.
27 . The combination of claim 23 wherein the non-nucleoside reverse transcriptase inhibitor is selected from the group consisting of atevirdine, delavirdine, nevirapine, capravirine, Calanolide A, dioxolane thymidine, BILR 355BS, SJ-3366, MIV-150, GSK-695634, GSK-678248, KP-1212 and TMC-278.
28 . The combination of claim 1 wherein the antiretroviral agent is a CCR5 inhibitor.
29 . The combination of claim 28 wherein the CCR5 inhibitor is maraviroc
30 . The combination of claim 1 wherein the antiretroviral agent is an integrase inhibitor.
31 . The combination of claim 30 wherein the integrase inhibitor is raltegravir.
32 . The combination of claim 1 wherein the antiretroviral agent is a fusion inhibitor.
33 . The combination of claim 32 wherein the fusion inhibitor is enfuvirtide.
34 . The combination of claim 1 wherein the first maturation inhibitor is administered substantially simultaneously with the antiretroviral agent selected from the group consisting of a protease inhibitor, a reverse transcriptase inhibitor, an integrase inhibitor, a CCR5 antagonist, a fusion inhibitor, and a second maturation inhibitor.
35 . The combination of claim 1 wherein the first maturation inhibitor is administered sequentially with the antiretroviral agent selected from the group consisting of a protease inhibitor, a reverse transcriptase inhibitor, an integrase inhibitor, a CCR5 antagonist, a fusion inhibitor, and a second maturation inhibitor.